AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
AbbVie (ABBV) shares dip as revenue drops 6% from last year
October 27, 2023 9:58 AM EDTAbbVie (NYSE: ABBV) shares dipped at the open Friday despite reporting its latest quarterly earnings that beat consensus expectations.
The pharmaceutical firm reported Q3 EPS of $2.95, $0.08 better than the analyst estimate of $2.87, while revenue for the quarter came in at $13.93 billion versus the consensus estimate of $13.71 billion.
The company's revenue dipped 6% from a year ago. Revenues from its immunology portfolio fell 11.3%, while its oncology segment... More
